Syncom Formulations (India) Limited (SYNCOMF) — Announcement | 8 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Resignation of Managing Director effective August 11, 2026
💡 Investor Takeaway
This leadership change may affect company strategy execution and investor confidence in the short term.

Syncom Formulations (India) Limited disclosed the resignation of Managing Director Vijay Shankarlal Bankda effective August 11, 2026, received by the company on August 8, 2026 at 2:35 PM, following SEBI regulatory requirements for material changes in leadership.

📄 View Original Announcement (PDF)

About Syncom Formulations (India) Limited (SYNCOMF)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹2,010.66 Cr P/E: 23.5 ROE: 25.0% ROCE: 32.9%

View full SYNCOMF stock details →

📡 Get AI alerts when SYNCOMF files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SYNCOMF — Free

📊 More SYNCOMF filings

See all SYNCOMF filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SYNCOMF files new disclosures

Track SYNCOMF filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SYNCOMF — Free

Free account · 2 AI queries/day